엑소좀 시장 규모, 점유율 및 동향 분석 보고서 : 제품 및 서비스별, 워크플로우별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Exosomes Market Summary

The global exosomes market size was valued at USD 229.3 million in 2025 and is anticipated to reach USD 1.2 billion by 2033, growing at a CAGR of 23.0% between 2026 and 2033. Exosomes, also termed Extracellular Vesicles (EVs), are enclosed in a single outer membrane.

Global Exosomes Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global exosomes market report based on product & service, workflow, application, end use, and region.

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Kits & Reagents
• Instruments
• Services
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Isolation Methods
  • Ultracentrifugation
  • Immunocapture on beads
  • Precipitation
  • Filtration
  • Others
• Downstream Analysis
  • Cell surface marker analysis using flow cytometry
  • Protein analysis using blotting & ELISA
  • RNA analysis with NGS & PCR
  • Proteomic analysis using mass spectroscopy
  • Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cancer
• Neurodegenerative diseases
• Cardiovascular diseases
• Infectious diseases
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & biotechnology companies
• Hospitals & diagnostics centers
• Academic & research institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
  • Singapore
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service Segment
  • 1.2.2. Workflow Segment
  • 1.2.3. Application Segment
  • 1.2.4. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Exosomes Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in Liquid Biopsy and Non-Invasive Diagnostics
    • 3.2.1.2. Growing Demand for Advanced Drug Delivery and Cancer Diagnostics
    • 3.2.1.3. Growth in government and non-government initiatives for exosome research
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent regulations pertaining to approval
    • 3.2.2.2. Challenges associated with the implementation of exosome-based therapies
  • 3.2.3. Market Challenges Analysis
  • 3.2.4. Market Opportunity Analysis
• 3.3. Case Study Insights
• 3.4. Exosomes Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's Five Forces Analysis
  • 3.4.2. PESTEL Analysis

Chapter 4. Exosomes Market: Product & Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Exosomes Market Product & Service Movement Analysis
• 4.3. Global Exosomes Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
• 4.4. Kits & reagents
  • 4.4.1. Kits & reagents market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Instruments
  • 4.5.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Services
  • 4.6.1. Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Exosomes Market: Workflow Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Exosomes Market Workflow Movement Analysis
• 5.3. Global Exosomes Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
• 5.4. Isolation Methods
  • 5.4.1. Isolation methods market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Ultracentrifugation
    • 5.4.2.1. Ultracentrifugation market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. Immunocapture on beads
    • 5.4.3.1. Immunocapture on beads market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.4. Precipitation
    • 5.4.4.1. Precipitation market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.5. Filtration
    • 5.4.5.1. Filtration market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.6. Others
    • 5.4.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Downstream Analysis
  • 5.5.1. Downstream analysis market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.2. Cell surface marker analysis using flow cytometry
    • 5.5.2.1. Cell surface marker analysis using flow cytometry market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.3. Protein Analysis using blotting & ELISA
    • 5.5.3.1. Protein Analysis using blotting & ELISA market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.4. RNA analysis with NGS & PCR
    • 5.5.4.1. RNA analysis with NGS & PCR market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.5. Proteomic analysis using mass spectroscopy
    • 5.5.5.1. Proteomic analysis using mass spectroscopy market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.6. Others
    • 5.5.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Exosomes Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Exosomes Market Application Movement Analysis
• 6.3. Global Exosomes Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Cancer
  • 6.4.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Neurodegenerative Diseases
  • 6.5.1. Neurodegenerative diseases market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Cardiovascular Diseases
  • 6.6.1. Cardiovascular diseases market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Infectious Diseases
  • 6.7.1. Infectious diseases market estimates and forecasts 2021 to 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Exosomes Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Exosomes Market End Use Movement Analysis
• 7.3. Global Exosomes Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Pharmaceutical & Biotechnology Companies
  • 7.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Hospitals & Diagnostics Centers
  • 7.5.1. Hospitals & diagnostics centers market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Academic & Research Institutes
  • 7.6.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Exosomes Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033
• 8.4. North America
  • 8.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Competitive scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Competitive scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Competitive scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Competitive scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Competitive scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Competitive scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Competitive scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Competitive scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Competitive scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Competitive scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.9. Denmark
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Competitive scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Competitive scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Competitive scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Competitive scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Competitive scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Competitive scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Competitive scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.8. Singapore
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Competitive scenario
    • 8.6.8.3. Regulatory Framework
    • 8.6.8.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Competitive scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Competitive scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Competitive scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Competitive scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Competitive scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key country dynamics
    • 8.8.5.2. Competitive scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2025
• 9.4. Company Profiles/Listing
  • 9.4.1. Bio-Techne Corporation
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Danaher Corporation
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Hologic Inc.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Fujifilm Holdings Corporation
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Lonza
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Miltenyi Biotec
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. QIAGEN
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Thermo Fisher Scientific, Inc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Abcam Plc
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. RoosterBio, Inc.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives